# Oncostellae SL

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oncostellae-sl

- Industry: Biotechnology
- Headquarters: Santiago de Compostela, Spain
- Website: www.oncostellae.com
- Total disclosed funding: $1.6M
- Latest round: Series A (Mar 14, 2024)
- Investors on record: 3

## About

Founded in 2013 and based in Santiago de Compostela, Spain, Oncostellae SL  is a clinical-stage biopharmaceutical company. The company was founded by Julio Castro. In March 2024, Oncostellae SL raised EUR 500,000 in Series A funding from the Center for Technological & Industrial Development, Noso Capital. As of 2024, the company is led by its CEO, Guido Kurz.

Oncostellae develop small-molecule drugs for use as drugs in oncology and inflammatory/automotive diseases. The firm’s pipeline product portfolio includes OST-122, a drug that targets inflammatory bowel disease (IBD); and OST-499, a drug being developed to treat uterine fibroids and other gynecological conditions.

The company plans to use the funds raised in March 2024 to accelerate its research and development of a therapeutic drug.

## Funding rounds

- Series A, Mar 14, 2024, $0.6M — Center for Technological & Industrial Development, Noso Capital
- Seed, Jan 26, 2016, $1.1M — Inveready Asset Management

## Investors

- Inveready Asset Management (https://capitalatlas.ai/funds/inveready-asset-management) — Seed
- Center for Technological & Industrial Development (https://capitalatlas.ai/funds/center-for-technological-industrial-development) — Series A
- Noso Capital (https://capitalatlas.ai/funds/noso-capital) — Series A